Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Cypherpunk Technologies (CYPH) Drops -58% in 30 Days on Zcash Swings

Cypherpunk Technologies (CYPH) Drops -58% in 30 Days on Zcash Swings

Key Takeaways

  • CYPH shares fell roughly 58% over the trailing 30 days, sliding from about $3.33 to near $1.40, pressured by Zcash price swings and heavy post-earnings selling.
  • The stock remains net higher over the trailing three months but has surrendered most of a late-September surge that peaked near $4.19.
  • Key influences include volatility in the price of Zcash (ZEC), third-quarter results driven largely by non-cash unrealized gains, a critical independent research note, and reported insider selling.
  • Cypherpunk runs a dual model: a Zcash treasury and mining operation alongside an oncology pipeline through its Leap Therapeutics subsidiary.
  • Cantor Fitzgerald raised its price target to $4.90 with an Overweight rating earlier in the period, while a separate research firm flagged governance and strategy concerns.
  • Because reported earnings are tied to Zcash's market value, CYPH carries above-average volatility relative to typical operating companies.
  • For deeper data, review CYPH's Price Targets, Earnings, and Forecast pages.

Company Background and Dual Strategy

Cypherpunk Technologies Inc. (CYPH) is a privacy-focused technology company headquartered in Cambridge, Massachusetts. Formerly known as Leap Therapeutics, the company rebranded in November 2025 and now pursues a dual-track strategy. Its primary focus is a digital asset treasury business anchored by Zcash, a privacy-preserving cryptocurrency, which the company accumulates through open-market purchases and its own mining operation, Cypherpunk Mining. Management has described a stated objective of building Zcash holdings toward at least 5% of the token's circulating supply over time.

Alongside this, the company continues oncology development through its Leap Therapeutics subsidiary, led by sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody being advanced toward a registrational Phase 3 trial in DKK1-high metastatic colorectal cancer, plus the preclinical FL-501 program. This unusual combination of a cryptocurrency treasury and a clinical-stage biopharmaceutical pipeline is why investors follow the stock, and it also explains much of its outsized price volatility. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, CYPH declined approximately 58%, falling from a close near $3.33 in late October to roughly $1.40 by mid-November. The selloff was broad and persistent rather than a single-day event, with the shares trending lower through early and mid-November before an additional sharp leg down following third-quarter earnings.

The trailing three-month picture is more nuanced. In mid-August, the stock traded near $1.19. It then rallied dramatically, reaching a 52-week high near $4.19 in late September as Zcash appreciated sharply, before reversing and giving back most of those gains. Measured end-to-end, the shares were still modestly higher over the full three-month window, but the dominant feature of the quarter was extreme volatility: a rapid run-up followed by a deep correction.

Factors Behind the Recent 30-Day Decline

Several factors combined to push CYPH lower over the past 30 days. The most important is the stock's direct linkage to Zcash. After a powerful rally through the third quarter, sentiment around the token cooled, and the value of Cypherpunk's treasury holdings moved in tandem, removing a key support for the share price.

Third-quarter results, reported in mid-November, added to the pressure. The company posted net income of roughly $306 million, but the figure was driven overwhelmingly by a non-cash unrealized gain on its Zcash holdings rather than operating cash flow. With the market focused on the sustainability of that gain, the stock declined following the release.

A critical report from Fugazi Research questioning the company's shift from its legacy biotech business to a Zcash treasury strategy also weighed on sentiment, as did reported insider selling activity without corresponding insider purchases. Together, these factors reinforced a risk-off tone that drove the shares sharply lower.

The Three-Month Rally and Its Reversal

The broader three-month story is defined by the extraordinary rally in Zcash and Cypherpunk's aggressive treasury build-out. The company launched what it describes as the world's largest Zcash mining fleet through an equity-based transaction with Winklevoss Capital, began generating its first mining revenue, and expanded its Zcash holdings toward roughly 2% of circulating supply. Cantor Fitzgerald responded by raising its price target to $4.90 from $1.60 while maintaining an Overweight rating, reflecting optimism about the treasury strategy.

However, the same mechanism that produced rapid gains also exposed shareholders to sharp drawdowns. As Zcash pulled back from its late-September peak, unrealized gains on the balance sheet contracted, and the stock retraced a large share of its prior advance. The quarterly net result therefore masks a high-volatility round trip that left the shares well below their intra-quarter high.

Key Drivers to Watch Going Forward

The single most important variable for CYPH remains the price of Zcash, which directly drives the value of the company's treasury and the scale of its reported unrealized gains and losses. Investors should monitor token price trends, mining output and uptime as the fleet reaches full-quarter operations, and progress toward the stated 5%-of-supply accumulation target.

On the biotech side, the strategic process underway for sirexatamab, which could result in a partnership, license, financing, or sale, represents a meaningful potential catalyst. Regulatory milestones and any update on the planned Phase 3 trial in colorectal cancer also matter. Additional considerations include share dilution from the company's equity issuance programs, insider transaction activity, and broader cryptocurrency market regulation and risk appetite. These factors make the outlook highly dependent on both digital asset markets and clinical execution rather than conventional operating fundamentals. From what I see, this is important because the volatility stems directly from those external variables.

AI Tools in My Research Process

When evaluating names with this level of complexity, I often rely on Tickeron’s AI Trend Prediction Engine to model potential scenarios based on historical patterns and current market conditions. It helps me cross-check the impact of Zcash movements alongside biotech milestones without relying solely on manual analysis. The platform’s AI Real Time Patterns feature also provides quick visibility into emerging setups across thousands of tickers, which I find useful for staying objective amid rapid price swings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CYPH

Momentum Indicator for CYPH turns negative, indicating new downward trend

CYPH saw its Momentum Indicator move below the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned negative. In 68 of the 75 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for CYPH turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 34 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

CYPH moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CYPH crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CYPH entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +21.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYPH advanced for three days, in 216 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. CYPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.228) is normal, around the industry mean (2.423). P/E Ratio (4.500) is within average values for comparable stocks, (8.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.318). Dividend Yield (0.000) settles around the average of (0.274) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (15.906).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

Notable companies

The most notable companies in this group are Ares Capital Corp (NASDAQ:ARCC), WisdomTree (NYSE:WT), AMTD Idea Group (NYSE:AMTD).

Industry description

Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.

Market Cap

The average market capitalization across the Investment Managers Industry is 8.92B. The market cap for tickers in the group ranges from 1.6 to 182.57B. BLK holds the highest valuation in this group at 182.57B. The lowest valued company is OXLCO at 1.6.

High and low price notable news

The average weekly price growth across all stocks in the Investment Managers Industry was -8%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -11%. BCG experienced the highest price growth at 65%, while SDEV experienced the biggest fall at -29%.

Volume

The average weekly volume growth across all stocks in the Investment Managers Industry was -2%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was 3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 65
P/E Growth Rating: 58
Price Growth Rating: 58
SMR Rating: 67
Profit Risk Rating: 81
Seasonality Score: 14 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in clinical stage immuno-oncology

Industry InvestmentManagers

Industry
Biotechnology
Address
47 Thorndike Street
Phone
+1 617 714-0360
Employees
6
Web
https://www.cypherpunk.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.